Zacks Investment Research Downgrades OncoGenex Pharmaceuticals Inc (OGXI) to Hold

Zacks Investment Research Downgrades OncoGenex Pharmaceuticals Inc (OGXI) to Hold


According to Zacks, "Oncogenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development.



from Biotech News